awmsg logo



5-aminolaevulinic acid (Ameluz®)


Reference No. 3372

Publication date:
19/10/2017


Appraisal information

5-aminolaevulinic acid (Ameluz®) 78 mg/g gel


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Skin
NMG meeting date: 06/09/2017
AWMSG meeting date: 11/10/2017
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2217
Ministerial ratification: 18/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

5-aminolaevulinic acid (Ameluz®) is recommended as an option for use within NHS Wales for the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment related morbidity and/or poor cosmetic outcome in adults.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download